AU2002236517A1 - Targetet retoviral vectors for cancer immunotherapy - Google Patents

Targetet retoviral vectors for cancer immunotherapy

Info

Publication number
AU2002236517A1
AU2002236517A1 AU2002236517A AU3651702A AU2002236517A1 AU 2002236517 A1 AU2002236517 A1 AU 2002236517A1 AU 2002236517 A AU2002236517 A AU 2002236517A AU 3651702 A AU3651702 A AU 3651702A AU 2002236517 A1 AU2002236517 A1 AU 2002236517A1
Authority
AU
Australia
Prior art keywords
targetet
retoviral
vectors
cancer immunotherapy
immunotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002236517A
Inventor
Erlinda M. Gordon
Frederick L Hall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of AU2002236517A1 publication Critical patent/AU2002236517A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/857—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from blood coagulation or fibrinolysis factors
AU2002236517A 2000-11-29 2001-11-29 Targetet retoviral vectors for cancer immunotherapy Abandoned AU2002236517A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25018500P 2000-11-29 2000-11-29
US60/250,185 2000-11-29
PCT/US2001/044804 WO2002044394A2 (en) 2000-11-29 2001-11-29 Targetet retoviral vectors for cancer immunotherapy

Publications (1)

Publication Number Publication Date
AU2002236517A1 true AU2002236517A1 (en) 2002-06-11

Family

ID=22946644

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002236517A Abandoned AU2002236517A1 (en) 2000-11-29 2001-11-29 Targetet retoviral vectors for cancer immunotherapy

Country Status (3)

Country Link
US (4) US20020177571A1 (en)
AU (1) AU2002236517A1 (en)
WO (1) WO2002044394A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177571A1 (en) * 2000-11-29 2002-11-28 Gordon Erlinda M. Targeted vectors for cancer immunotherapy
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
ATE513471T1 (en) * 2003-04-21 2011-07-15 Epeius Biotechnologies Corp METHODS AND COMPOSITIONS FOR TREATING DISEASES
US20060019396A1 (en) * 2004-06-07 2006-01-26 Tissuegene, Inc. Retroviral vectors with enhanced efficiency of transgene expression and safety
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
KR20110022251A (en) * 2009-08-27 2011-03-07 삼성전자주식회사 Method and apparatus for encoding/decoding stereo audio
SG10201808738WA (en) * 2013-07-18 2018-11-29 Vib Vzw Fusokines involving cytokines with strongly reduced receptor binding affinities
WO2018144863A1 (en) * 2017-02-04 2018-08-09 Gordon Erlinda M Cyclin g1 inhibitors and related methods of treating cancer
CA3113618A1 (en) * 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH684094A5 (en) 1988-03-21 1994-07-15 Viagene Inc Recombinant retro:viruses carrying vector construct
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69129897T2 (en) * 1990-10-25 1998-12-17 Clague Pitman Hodgson METHOD OF GENTRANSFER BY MEANS OF RETROTRANSPOSONS
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
JPH09507744A (en) 1993-10-22 1997-08-12 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム A novel fission phosphoprotein: mitocin
DE69515028T2 (en) 1994-03-22 2000-06-29 Immune Response Corp Inc THE HIGHLY EFFICIENT PRODUCTION AND INSULATION OF VIRUS PARTICLES
US5643770A (en) * 1994-07-21 1997-07-01 Alexion Pharmaceuticals, Inc. Retroviral vector particles expressing complement inhibitor activity
WO1996004934A1 (en) 1994-08-17 1996-02-22 Genetic Therapy Inc. Retroviral vectors produced by producer cell lines resistant to lysis by human serum
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
WO1996030504A1 (en) 1995-03-24 1996-10-03 Genetic Therapy, Inc. Modified viral envelope polypeptide
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5800811A (en) 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
EP1023467B1 (en) 1996-07-09 2004-03-03 CANJI, Inc. Method for measuring viral infectivity
CA2595915A1 (en) 1997-01-31 1998-08-06 Schering Corporation Methods for cultivating cells and propagating viruses
EP0973538B1 (en) * 1997-04-10 2008-03-12 University of Southern California Modified proteins which bind extracellular matrix components
US6004798A (en) 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
EP1259605B1 (en) 2000-03-02 2007-05-16 University of Southern California Mutated cyclin g1 protein
US7060811B2 (en) * 2000-10-13 2006-06-13 Board Of Regents, The University Of Texas System WWOX: a tumor suppressor gene mutated in multiple cancers
US20020177571A1 (en) 2000-11-29 2002-11-28 Gordon Erlinda M. Targeted vectors for cancer immunotherapy
CA2449087A1 (en) * 2001-08-30 2003-03-13 Tolemac, Llc Antiprotons for imaging and termination of undesirable cells
CN1604988A (en) 2002-11-11 2005-04-06 饭塚孝司 Rotary filter type microparticle removing equipment
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
ATE513471T1 (en) * 2003-04-21 2011-07-15 Epeius Biotechnologies Corp METHODS AND COMPOSITIONS FOR TREATING DISEASES
ES2426816T3 (en) * 2004-08-04 2013-10-25 Mentrik Biotech, Llc Fc regions variants

Also Published As

Publication number Publication date
US20020177571A1 (en) 2002-11-28
US20150031625A1 (en) 2015-01-29
US20060251627A1 (en) 2006-11-09
US8828378B2 (en) 2014-09-09
WO2002044394A2 (en) 2002-06-06
WO2002044394A3 (en) 2003-02-06
US20100233127A1 (en) 2010-09-16
US7708986B2 (en) 2010-05-04

Similar Documents

Publication Publication Date Title
AU2002247304A1 (en) Anti-neovasculature preparations for cancer
AU2002360766A1 (en) Methods for cancer imaging
AU2001212331A1 (en) Hiking exercice apparatus
EP1220456A3 (en) Arrangement for antenna matching
AUPR395801A0 (en) Antibodies against cancer
AU2002254570A1 (en) Epitope sequences
AU2002357049A1 (en) Methods for preparing 0-desmethylvenlafaxine
AU2002235141A1 (en) Glycosyltransferase vectors for treating cancer
AU7636600A (en) Slide apparatus
GB9927328D0 (en) Immunotherapy
AU2001290860A1 (en) Spas-1 cancer antigen
AU2002349543A1 (en) Tumor antigens
AU2001232054A1 (en) Vector
AU2003292405A1 (en) Cancer immunotherapy using polycomb proteins
AU2002236517A1 (en) Targetet retoviral vectors for cancer immunotherapy
AU2003228792A1 (en) Adenovirus vectors for immunotherapy
AU6278300A (en) Tumor-associated antigen (r11)
AU2003264488A1 (en) Immunotherapeutic for cancer
AU2001246703A1 (en) Dna immunization vectors
AU2001236470A1 (en) Ovarian tumor-associated sequences
AU2001242342A1 (en) Antiperspirants
AU2001220281A1 (en) Rollerboard for road-skiing
AU2002251211A1 (en) Antenna system
AU3283500A (en) Tumor-associated antigen
AU4924000A (en) Tumor-associated antigen (c42)